-
Published01/02/2023
-
Deadline31/01/2024
-
Today04/12/2024
-
Opening of tenders31/03/2025
Utilities
- indicates text translated automatically in your browsing language
Germany-Erfurt: Pharmaceutical products
The subject of this publication is the conclusion of non-exclusive discount agreements under § 130a(8) SGB V on medicinal products containing the active substance Dasatinib (WHO ATC code: L01EA02). The contract is based on an open-house model, i.e. a contract is open to all interested pharmaceutical companies within the participation period, provided that they meet and accept the conditions for participation. As a result, individual contractual negotiations are not conducted and there is no (supply) exclusivity. It should be noted that the volume of purchases is unknown, as it depends on demand and changes in the number of insured persons, on doctors’ regulatory behaviour and on the dispensing and stockpiling behaviour of public pharmacies. In the same vein, minimum quantities of purchases are not guaranteed. For more information, please refer to point II.2.4) of the contract notice. Text automatically translated in your browsing language Automatically translated
Official name: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
Postal address: Augustinerstraße 38
Town: Erfurt
NUTS code: DEG
Postal code: 99084
Country: DEU
Contact person: Unternehmensbereich Corporate Governance, Geschäftsbereich Zentrale Vergabestelle
Main address: https://plus.aok.de/
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.